Skip to main navigation

+44 (0)20 8154 4600
info@achillestx.com

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Press Releases

Home
About Us
Science
Publications
Pipeline
- PIPELINE
- EXPANDED ACCESS
Investors & Media
CAREERS
Contact

Year

All News
2024
2023
2022
2021
2020
2019
2018
2017
2016

Dec 20 2022

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More +

Dec 6 2022

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

Read More +

Nov 30 2022

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

Read More +

Nov 22 2022

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

Read More +

Nov 8 2022

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Read More +

Oct 6 2022

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Read More +

Aug 9 2022

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Read More +

Jul 21 2022

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Read More +

Jun 30 2022

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Read More +

Jun 21 2022

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

Read More +

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Print Page

RSS Feeds

Email Alerts

Contact IR

Home
About Us
Science
Publications
Pipeline
Investors & Media
Work with us
Contact

UK Headquarters:
Achilles Therapeutics plc
245 Hammersmith Road
London
W6 8PW, UK

US Headquarters:
Achilles Therapeutics US, Inc.
401 N. Broad Street
Suite M121
Philadelphia, PA 19108

+44 (0)20 8154 4600
info@achillestx.com

© Copyright - Achilles Therapeutics plc.

Achilles Therapeutics plc (13027460) is registered in England and Wales. The registered office is at 245 Hammersmith Road, London, W6 8PW.

Privacy & Cookie Policy

Terms & Conditions